HomeCompareCIT vs PFE

CIT vs PFE: Dividend Comparison 2026

CIT yields 14.03% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CIT wins by $4462618.91M in total portfolio value
10 years
CIT
CIT
● Live price
14.03%
Share price
$53.50
Annual div
$7.51
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4462618.96M
Annual income
$4,402,331,954,946.55
Full CIT calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — CIT vs PFE

📍 CIT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCITPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CIT + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CIT pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CIT
Annual income on $10K today (after 15% tax)
$1,192.38/yr
After 10yr DRIP, annual income (after tax)
$3,741,982,161,704.57/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, CIT beats the other by $3,741,982,139,384.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CIT + PFE for your $10,000?

CIT: 50%PFE: 50%
100% PFE50/50100% CIT
Portfolio after 10yr
$2231309.50M
Annual income
$2,201,165,990,602.63/yr
Blended yield
98.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CIT
Analyst Ratings
14
Buy
13
Hold
Consensus: Buy
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CIT buys
0
PFE buys
0
No recent congressional trades found for CIT or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCITPFE
Forward yield14.03%6.13%
Annual dividend / share$7.51$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$4462618.96M$49.6K
Annual income after 10y$4,402,331,954,946.55$26,258.71
Total dividends collected$4458578.66M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: CIT vs PFE ($10,000, DRIP)

YearCIT PortfolioCIT Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$13,506$2,805.61$9,153$693.39+$4.4KCIT
2$21,534$7,082.51$8,593$849.25+$12.9KCIT
3$44,148$21,107.37$8,336$1,066.78+$35.8KCIT
4$128,126$80,887.02$8,437$1,384.80+$119.7KCIT
5$575,875$438,780.98$9,013$1,875.40+$566.9KCIT
6$4,302,452$3,686,264.84$10,306$2,680.72+$4.29MCIT
7$56,081,450$51,477,826.78$12,820$4,101.38+$56.07MCIT
8$1,314,215,448$1,254,208,296.50$17,673$6,826.70+$1314.20MCIT
9$56,342,993,216$54,936,782,686.28$27,543$12,591.86+$56342.97MCIT
10$4,462,618,957,687$4,402,331,954,946.55$49,560$26,258.71+$4462618.91MCIT

CIT vs PFE: Complete Analysis 2026

CITStock

CIT Group Inc. operates as the holding company for CIT Bank, N.A. that provides banking and related services to commercial and individual customers. The company operates through Commercial Banking and Consumer Banking segments. The Commercial Banking segment provides a range of commercial lending, leasing, and deposit products; loans comprising revolving lines of credit, term loans, unsecured loans, collateral-backed loans, asset-based loans, commercial real estate loans, and cash flow loans; and ancillary services and products, including cash management, capital markets, and advisory services primarily to small and middle market companies. This segment also offers asset management, factoring, receivable management, and secured financing services; supply chain financing, leasing and equipment financing to small businesses and middle market, and railroads and shippers. The Consumer Banking segment provides checking, savings, money market, and individual retirement accounts; time deposits and certificates of deposit; residential mortgage loans; small business administration loans; payment solutions; and fiduciary services. The company also offers leasing and advisory, and online banking services. It operates through a network of approximately 60 branches located in southern California. CIT Group Inc. was founded in 1908 and is based in New York, New York.

Full CIT Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CIT vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CIT vs SCHDCIT vs JEPICIT vs OCIT vs KOCIT vs MAINCIT vs JNJCIT vs MRKCIT vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.